|
|
various. (1994). Syringe and Needle Exchange to Prevent HIV Infection. JAMA : the journal of the American Medical Association, 271(23; 15.06.1994), 1825–1827.
|
|
|
|
Watters, J. K., Estilo, M. J., Clark, G. L., & Lorvick, J. (1994). Syringe and Needle Exchange as HIV/AIDS Prevention for Injection Drug Users. JAMA : the journal of the American Medical Association, 271(2; 12.01.1994), 115–120.
|
|
|
|
Help Stop AIDS. (1990). Syringe access research bibliography (by category). Sacramento: Californians for Responsible Syringe Policy (CRSP).
Keywords: harm reduction; needle distribution and exchange; research; prevention; cost (economic); study; pharmacy; physician; medical waste disposal; law; public policy; United States; bibliography
|
|
|
|
Burris, S., Strathdee, S. A., & Vernick, J. S. (2002). Syringe access law in the United States : a state of the art assessment of law and policy. Baltimore: Center for Law and the Public's Health at Johns Hopkins and Georgetown Universities, Johns Hopkins Bloomberg School of Public Health.
Keywords: public policy; harm reduction; needle distribution and exchange; laws and regulations; assessment; United States
|
|
|
|
Ruiz-Sierra, J. (2001). Syringe access. Berkeley: Drug Policy Alliance (DPA).
Keywords: harm reduction; needle distribution and exchange; prevention; HIV infection; Aids; pharmacy; government and politics; public health; public policy; United States
|
|
|
|
European Monitoring Centre for Drugs and Drug Addiction. (2013). Synthetic drug production in Europe. Lisbon: Author.
Abstract: Europe has a long history of producing and consuming synthetic drugs. The region remains important today for the production of these substances, with manufacture taking place for both domestic consumption and export to other parts of the world. In terms of both production and use, three substances dominate the European market for synthetic drugs: amphetamine (usually the sulphate salt), ecstasy-type drugs, especially methylenedioxymethamphetamine (MDMA), and methamphetamine (usually the hydrochloride salt).
Keywords: psychoactive substances; illegal production of drugs; AOD consumption; drug trafficking; amphetamines; MDMA; ecstasy; international area; Europe; European Union
|
|
|
|
European Monitoring Centre for Drugs and Drug Addiction. (2013). Synthetic cannabinoids in Europe. Lisbon: Author.
Abstract: Synthetic cannabinoids, or more correctly, synthetic cannabinoid receptor agonists, mimic the effect of cannabis and are the largest group of compounds monitored at European level by the EU Early warning system on new psychoactive substances (EWS). ’Legal high’ products containing synthetic cannabinoids have probably been sold as herbal smoking mixtures since at least 2006. These products do not necessarily contain tobacco or cannabis but when smoked, produce effects similar to those of cannabis. They have been subject to innovative marketing approaches and are widely available on the Internet and in some shops in urban areas (often called ’head’ or ’smart’ shops).
Keywords: psychoactive substances; cannabis product; cannabinoids; smoking; tobacco in any form; AOD effects and AODR problems; adverse drug effect; AOD product advertising; AOD sales outlet; international area; Europe; European Union
|
|
|
|
Klingemann, H., Müller, R., & Voll, P. (1998). Synthesebericht Alkoholismus und Erwerbsfähigkeit. Lausanne: Schweizerische Fachstelle für Alkohol- und andere Drogenprobleme (SFA).
Keywords: addiction; AOD dependence; chemical addiction; alcohol; work; workplace context; stigma
|
|
|
|
Eastus, C. (2009). Symposium act-info 2009 : Suchtmittelkonsum in der Schweiz – Trends und neue Herausforderungen. Spectra : Gesundheitsförderung und Prävention, (72; 01/2009), 5.
Keywords: monitoring; AOD use; Switzerland
|
|
|
|
Eastus, C. (2009). Symposium act-info 2009 : consommation de substances psychotropes en Suisse – tendances et nouveaux défis. Spectra : prévention et promotion de la santé, (72; 01/2009), 5.
Keywords: monitoring; AOD use; Switzerland
|
|
